aflibercept + oxaliplatin + leucovorin + fluorouracil
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucinous Adenocarcinoma of the Colon
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Trial Timeline
Nov 14, 2012 → Aug 30, 2022
NCT ID
NCT01652196About aflibercept + oxaliplatin + leucovorin + fluorouracil
aflibercept + oxaliplatin + leucovorin + fluorouracil is a phase 2 stage product being developed by Sanofi for Mucinous Adenocarcinoma of the Colon. The current trial status is completed. This product is registered under clinical trial identifier NCT01652196. Target conditions include Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01652196 | Phase 2 | Completed |
Competing Products
2 competing products in Mucinous Adenocarcinoma of the Colon
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cetuximab | Eli Lilly | Phase 2 | 52 |
| panitumumab + irinotecan hydrochloride + fluorouracil + leucovorin calcium | Amgen | Phase 2 | 51 |